Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

14 Dec 2012

• By John Davis

Related Content

Alexza Expects FDA, EU Regulatory Decisions On Adusave This December

09 Aug 2012

Lundbeck Pins Hopes On New Product Launches, Ex-Europe Growth To Reverse Revenue Drain

08 Nov 2012

Disease Severity Underlies Advisory Committee Support For <em>Kynamro</em>

19 Oct 2012

Final <em>Perjeta</em> Overall Survival Data Delayed By Its Efficacy

08 Dec 2012

Perjeta Approval Heralds Roche’s Next Wave Of Breast Cancer Drugs

10 Jun 2012

Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline

07 Sep 2012

Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology

07 Jan 2008

Related Companies

Roche Holding AG

Alexza Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Vanda Pharmaceuticals, Inc.

Forest Laboratories, Inc.

Biotie Therapies Corp.

Sanofi

Genentech, Inc.

Grupo Ferrer Internacional, S.A.

Additional Topics

Europe BioPharmaceutical

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.